Opendata, web and dolomites

LIPOBITS SIGNED

Liposome-based Biomimetic Treatment for auto-immune diabetes (T1D)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIPOBITS project word cloud

Explore the words cloud of the LIPOBITS project. It provides you a very rough idea of what is the project "LIPOBITS" about.

preclinical    treatments    solution    lower    tolerance    diabetes    exogenous    physiologic    roadmap    proprietary    ipr    platform    preventive    despite    lt    considering    containing    assays    scaling    feasibility    mechanism    palliative    insulins    10    antigen    incidence    glycaemic    worldwide    therapeutic    cycle    therapies    complementary    toxicity    acute    solid    prevent    total    none    immune    market    deeper    steady    biomimetic    company    insulin    stopping    immunosuppressive    permanent    beta    lipobits    society    continuous    competitors    lasting    ad    autoimmune    onset    ahead    liposome    enlarging    discover    t1d    2022    vaccine    cure    advantages    foreseen    innovative    competitive    start    ing    disease    encapsulation    administration    recover    cells    sustained    life    detected    mainly    incomes    autoantigens    auto    producing    systemic    asset    effect    licensees    induce    dimension    300    population    jobs    liposomes    chronic    models    generate    network    treatment    action    regulatory    secondary    qualified    animal    validated    diseases    quality    innovation    reverse    global    reaction    strategy    therapeutics    marketed   

Project "LIPOBITS" data sheet

The following table provides information about the project.

Coordinator
AHEAD THERAPEUTICS SL 

Organization address
address: EDIFICI EUREKA PARC RECERCA UAB CAMPUS UAB S/N
city: CERDANYOLA DEL VALLES
postcode: 8193
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.aheadtherapeutics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AHEAD THERAPEUTICS SL ES (CERDANYOLA DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Autoimmune diseases (AD) affect 5-10% of the global population and require chronic palliative treatments, resulting in lower quality of life and great costs for society. Moreover, a steady rise in the incidence of some AD such as Type 1 diabetes (T1D) has been detected worldwide. Main treatments for T1D are currently based on the continuous administration of exogenous insulin, but none of the 20 existing marketed insulins can achieve a sustained glycaemic level control. Thus, they cannot fully prevent T1D’s long term and acute side effects.

Ahead Therapeutics is a start-up company exploiting a proprietary encapsulation technology to develop treatments for different AD. It has developed an innovative solution for T1D based on the use of liposomes containing auto-autoantigens. Through a biomimetic process, these liposomes can induce antigen specific immune tolerance, stopping the autoimmune reaction and allowing insulin-producing β-cells to recover. Despite its potential for preventive use, Ahead’s treatment is mainly foreseen as a therapeutic reverse vaccine on the onset of T1D, leading to a permanent cure of the disease.

Ahead solution has several competitive advantages derived from its biomimetic/physiologic mechanism of action: long-lasting/permanent effect, non-systemic immunosuppressive, no secondary effects/toxicity, low-cost production, complementary with other therapies. The liposome-based platform has already been validated in animal models and preclinical non-regulatory assays are being completed. Current feasibility study will be now focus on defining a Regulatory Roadmap & IPR strategy, enlarging key partners network, discover new potential licensees, scaling up liposomes production and analyse deeper market & competitors.

LIPOBITS is a solid high-potential innovation project expected to support Ahead’s global dimension and to generate 7 high qualified jobs total incomes of 10,5 M€ by 2022, and < 300 M € considering the whole life cycle of the asset.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIPOBITS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIPOBITS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

STURSKIN (2018)

Innovative products by using tanned sturgeon skin

Read More